Omega-3 supplements may raise cognitive decline risk in Alzheimer's gene carriers
Updated
Updated · ScienceAlert · May 2
Omega-3 supplements may raise cognitive decline risk in Alzheimer's gene carriers
11 articles · Updated · ScienceAlert · May 2
A China-led observational study of more than 800 ADNI participants found faster MMSE decline among supplement users, especially those carrying the APOE ε4 risk variant.
Researchers said the association was not explained by amyloid plaques, tau tangles or grey matter loss, but was most closely linked to changes in neuronal synaptic function.
The authors cautioned the findings do not prove causation and may not generalise widely, but add to evidence that dose and patient context may determine whether omega-3 helps or harms cognition.
Could a common Alzheimer's gene turn your omega-3 supplement from a brain booster into a cognitive threat?
Scientists warn of an omega-3 'sweet spot.' Is your daily supplement dose actually harming your brain's health?
High-Dose DHA Supplementation (2g/day) as a Targeted Alzheimer’s Prevention Strategy for APOE4 Carriers: Insights from 2023-2026 Clinical Trials
Overview
Recent clinical trials highlight that high-dose DHA supplementation (around 2 grams daily) shows cognitive benefits specifically for individuals carrying the APOE4 gene, who have impaired brain uptake and faster metabolism of DHA. This genetic difference means APOE4 carriers require earlier and higher-dose intervention to effectively protect against Alzheimer's disease. Supplementing with B vitamins alongside DHA further supports brain health by reducing atrophy and cognitive decline. In contrast, omega-3 supplementation in the general elderly population shows limited benefit, emphasizing the need for personalized prevention strategies focused on genetic risk and timely, adequate dosing.